An experimental drug could shrink tumours by 30 per cent , scientists say. For 12,000 men a year with prostate cancer their treatment stops working. READ MORE:A new drug for prostate cancer could extend the lives of thousands of men.
But aggressive prostate cancer finds a 'plan B' and replaces testosterone with another type of fuel, so the drugs stop working. Researchers plan to recruit more men to find out exactly how much extra time with their families the treatment could give patients with aggressive prostate cancer. 'This is tremendously exciting and it suggests we have an entirely new way to treat prostate cancer on the horizon.'
But prostate cancer can apparently make them change their behaviour entirely - so that they instead enter tumours to help them grow and spread. After receiving AZD5069, in combination with enzalutamide, to prevent testosterone fuelling their cancer, men had a lower level of cancer cells in their blood, and a lower level of a protein called PSA which is elevated in men with prostate cancer.
It means prostate cancer is behind only lung and bowel in terms of how many people it kills in Britain.Despite this, it receives less than half the research funding of breast cancer and treatments for the disease are trailing at least a decade behind.Every year, upwards of 52,300 men are diagnosed with prostate cancer in the UK - more than 140 every day.Prostate cancer usually develops slowly, so there may be no signs someone has it for many years, according to the NHS.